Structure- based drug discovery of a selective, covalent KRas G12C inhibitor with oral activity in animal models of cancer

被引：0
|
作者：
Fischer, John [1 ]
Baer, Brian [1 ]
Ballard, Joshua [1 ]
Blake, James [1 ]
Bouhana, Karyn [1 ]
Brandhuber, Barbara [1 ]
Briere, David [2 ]
Burgess, Laurence [1 ]
Burkard, Michael [1 ]
Chiang, Harrah [2 ]
Chicarelli, Mark [1 ]
Christensen, James [2 ]
Davidson, Kevin [1 ]
Gaudino, John [1 ]
Hallin, Jill [2 ]
Hanson, Lauren [1 ]
Hee, Kenneth [1 ]
Hicken, Erik [1 ]
Hinklin, Ronald [1 ]
Marx, Matthew [2 ]
Mejia, Macedonio [1 ]
Olson, Peter [2 ]
Savechenkov, Pavel [1 ]
Sudhakar, Niranjan [2 ]
Tang, Tony [1 ]
Vigers, Guy [1 ]
Zecca, Henry [1 ]
Fell, Jay [1 ]
机构：
[1] Array Biopharma Inc, Boulder, CO USA
[2] Mirati Therapeut, San Diego, CA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2018年 / 256卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
144
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Structure-based drug discovery of MRTX1257: A selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer
    Marx, Matthew
    Baer, Brian
    Ballard, Joshua
    Blake, James
    Bouhana, Karyn
    Briere, David
    Burgess, Laurence
    Burkhard, Michael
    Chiang, Harrah
    Chicarelli, Mark
    Christensen, James
    Fischer, John
    Hallin, Jill
    Mejia, Macedonio
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony
    Vigers, Guy
    Fell, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [2] Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer.
    Marx, Matthew A.
    Baer, Brian R.
    Ballard, Joshua
    Blake, James F.
    Bouhana, Karyn
    Briere, David M.
    Burgess, Laurence E.
    Burkhard, Michael R.
    Chiang, Harrah
    Chicarelli, Mark J.
    Christensen, James G.
    Fischer, John P.
    Hallin, Jill
    Mejia, Macedonia J.
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony P.
    Vigers, Guy P.
    Fell, Jay B.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 67 - 68
  • [3] Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry
    Tran, John C.
    Hunsaker, Thomas
    Bell, Christina
    Ma, Taylur P.
    Chan, Emily
    Larrocha, Pablo Saenz-Lopez
    Homyk, Kelsey
    Liu, Liling
    La, Hank
    Mao, Jialin
    de la Cruz, Cecile C.
    Yu, Kebing
    Beresini, Maureen
    Forrest, William F.
    Xiao, Yang
    Jang, Anne
    Samus, Natalia
    Stesco, Nicholas Dupuis
    Mentinova, Marija
    Parent, Stephane
    Pottiez, Gwenael
    Schirm, Michael
    Purkey, Hans E.
    Liu, Yichin
    Merchant, Mark
    ANALYTICAL CHEMISTRY, 2023, 95 (11) : 4834 - 4839
  • [4] Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
    Zeng, Mei
    Lu, Jia
    Li, Lianbo
    Feru, Frederic
    Quan, Chunshan
    Gero, Thomas W.
    Ficarro, Scott B.
    Xiong, Yuan
    Ambrogio, Chiara
    Paranal, Raymond M.
    Catalano, Marco
    Shao, Jay
    Wong, Kwok-Kin
    Marto, Jarrod A.
    Fischer, Eric S.
    Janne, Pasi A.
    Scott, David A.
    Westover, Kenneth D.
    Gray, Nathanael S.
    CELL CHEMICAL BIOLOGY, 2017, 24 (08): : 1005 - +
  • [5] Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors
    Bae, Jae Hyun
    Lew, Erin D.
    Feng, Jun
    Gonzalez-Lopez, Marcos
    Oh, Joanne
    Fagan, Patrick
    Salie, Matt
    Isley, Nick
    Lam, Richard
    Irimia, Adriana
    Nevarez, Robin
    Lin, Bingzhen
    Congdon, Taylor
    Zhang, Jingchuan
    Xuan, Dawei
    Chen, Ping
    Vernier, Jean-Michel
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
  • [6] ALTA3263: an oral, KRAS isoform-selective, dual ON/OFF state, non-covalent inhibitor induces regressions across KRAS G12V, G12D, and G12C cancer models
    Wang, T.
    Ibanez, M.
    Yu, K.
    Fan, K.
    Juan, J.
    Perez, M.
    Smith, T.
    Walsh, B.
    Kang, V.
    Tyhonas, J.
    Alvarez, N.
    Tran, J.
    Moorefield, K. S.
    Phimister, A.
    Zhu, X.
    Chi, A.
    Bartberger, M. D.
    Murphy, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S5 - S6
  • [7] Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor
    Maddess, Matthew L.
    Sloman, David L.
    Ma, Xiaoshen
    Palani, Anandan
    Stoeck, Alexander
    Sather, Aaron C.
    Solban, Nicolas
    Duggal, Ruchia
    Ballard, Jeanine
    Munsell, Erik V.
    Chen, Lin-Chi
    Han, Yongxin
    Miller, Richard
    Gathiaka, Symon
    Brynczka, Christopher
    Li, Hongming
    Yang, Ruojing
    Brynczka, Christopher
    Day, Phil
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [8] Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
    Li, Ling
    Wu, Yinrong
    Yang, Zichao
    Xu, Chenglong
    Zhao, Huiting
    Liu, Jin
    Chen, Jingxuan
    Chen, Jianjun
    BIOORGANIC CHEMISTRY, 2021, 117
  • [9] Application of Compositions Comprising a KRAS G12C Inhibitor and an EGFR Inhibitor for the Potential Treatment of Cancer
    Kargbo, Robert B.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (09): : 1400 - 1401
  • [10] Second-Generation Atroposelective Synthesis of KRAS G12C Covalent Inhibitor GDC-6036
    Xu, Jie
    Lim, Ngiap-Kie
    Timmerman, Jacob C.
    Shen, Jeff
    Clagg, Kyle
    Orcel, Ugo
    Bigler, Raphael
    Trachsel, Etienne
    Meier, Roland
    White, Nicholas A.
    Burkhard, Johannes A.
    Sirois, Lauren E.
    Tian, Qingping
    Angelaud, Remy
    Bachmann, Stephan
    Zhang, Haiming
    Gosselin, Francis
    ORGANIC LETTERS, 2023, 25 (19) : 3417 - 3422
12345